Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Advances clinical research capabilities with leading regulatory grade registries platform
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Subscribe To Our Newsletter & Stay Updated
